Brainstorm Cell Therapeutics appoints Dr. Menghis Bairu to Board; Director Sankesh Abbhi to retire

BRAINSTORM CELL THERAPEUTICS INC.

Bairu appointed to Board effective Oct 28, 2021; receives $30K annual cash award in biannual installments.
Bairu is founder/CEO of Proxenia Venture Partners and Chairman/CEO of Bairex.
Abbhi will not stand for re-election at 2021 Annual Meeting; retirement not due to any dispute.
Abbhi served on Board since March 30, 2020.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Menghisteab Bairu

Director

BCLI · BRAINSTORM CELL THERAPEUTICS INC.

Effective: 2021-10-28
Filed: October 29, 2021, 7:59 PM ET

the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”) increased the size of the Board by one member and elected Dr. Menghisteab Bairu to serve as a member of the Board, effective October 28, 2021.

Departed

Sankesh Abbhi

Director

BCLI · BRAINSTORM CELL THERAPEUTICS INC.

Filed: October 29, 2021, 7:59 PM ET

On October 27, 2021, Sankesh Abbhi informed the Board of his intention not to stand for re-election at the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”), and to retire from the Board effective immediately prior to the commencement of the Annual Meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Menghisteab Bairu was elected as Director at BRAINSTORM CELL THERAPEUTICS INC..

Action: elected
Role: Director

Exact text from the filing

the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”) increased the size of the Board by one member and elected Dr. Menghisteab Bairu to serve as a member of the Board, effective October 28, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sankesh Abbhi departed as Director at BRAINSTORM CELL THERAPEUTICS INC..

Action: not stand for re-election and retire
Role: Director

Exact text from the filing

On October 27, 2021, Sankesh Abbhi informed the Board of his intention not to stand for re-election at the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”), and to retire from the Board effective immediately prior to the commencement of the Annual Meeting.

View on SEC.gov

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-21-131777

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.